Webinars and Sponsored Roundtables — Register Now
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Abbott
| Company | Abbott |
|---|---|
| Name of analyzer | CELL-DYN Emerald† |
| Contact | James Pickering |
| City, State | Lake Forest, IL |
| Phone | 800-323-9100 |
| Website | |
| Analyzer application | diagnostic use |
| Dimensions of analyzer (H × W × | 13.8 × 9.8 × 13.8 in./— |
| Country where analyzer was | U.S./Germany |
| First year analyzer was sold in U.S./Approximate No. of units installed in U.S.* | 2009/766 |
| First year analyzer sold outside | 2008/1, 513 |
| Foreign locations where company | Brazil, Canada, Italy, Japan, Saudi Arabia, Spain, U.K., Vietnam, more (installed in the aforementioned countries) |
| Human languages (other than | French, Italian, German, Spanish, Bulgarian, more |
| Analyzer list price | — |
| • Analyzer acquisition options | purchase, trade in, lease, reagent rental agreement |
| Training included with purchase/Total time for basic training per operator | 15 min. weekly; ~10 min. biannualy |
| • Follow-up training available | yes (extra charge) |
| Parameters that analyzer tests and reports | %&# lymphocytes, %&# neutrophils, Hb, Hct, MCH, MCHC, MCV, PLT, RBC, WBC, more |
| Types of testing FDA cleared or approved for analyzer | — |
| Types of body fluids FDA cleared or approved for analysis on analyzer | — |
| Analytical measurement range for body fluid | — |
| Precision for body fluid | — |
| Accuracy for body fluid | — |
| Automated differential performed for body fluids | — |
| Tests available for research use only | — |
| Differential methods used | electrical impedance counting |
| Analytical measurement range: • WBC count/RBC count | WBC: 0.4–96.1 K/µL/RBC: 0.22–7.61 M/µL |
| Precision: • WBC count/RBC count | WBC: 3.5% CV/RBC: 2.0% CV |
| Accuracy: • WBC count/RBC count | — |
| Interfering substances: • WBC/RBC | cryoglobulin, cryofibrinogen, heparin, monoclonal proteins, NRBCs, platelet clumping, unlysed RBCs, clotting, smudge cells, more/cryoglobulin, cryofibrinogen, giant platelets, high WBC count (>50, 000 K/µL), autoagglutination, more |
| • Hemoglobin/Platelets | carboxyhemoglobin (>10%), cryoglobulin, cryofibrinogen, in vivo hemolysis, heparin, high WBC count (>50, 000 K/µL), more/cryoglobulin, cryofibrinogen, in vivo and in vitro hemolysis, microcytic RBCs, RBC inclusions, more |
| • Hematocrit/Reticulocytes | cryoglobulin, cryofibrinogen, giant platelets, high WBC count (>50, 000 K/μL), hyperglycemia (>600 mg/dL), autoagglutination, clotting, in vitro hemolysis, more/— |
| • Automated differential | platelet aggregates, NRBCs, giant platelets, cryoglobulin, incomplete lysis of RBCs, small lymphocytes, fibrin clots, more |
| Throughput: max. CBCs per hour/Max. CBCs with differentials per hour | 57/57 |
| • Max. No. of slides processed per hour if stainer included | — |
| FDA-cleared or -approved sample container types (besides potassium EDTA) | none |
| Min. specimen volume open mode/Closed mode/Microsample capability | 9.8 µL/—/no |
| Types of patient data archived/Max. No. of archived patient data accessible when analyzer online | patient demographics, previous test results, more (customizable)/300, 000 on USB, 1, 500 results on internal memory |
| Analyzer performs delta checks | no |
| Parameters for which flags may appear | dispersed data alerts, suspect measurand flags, count invalidation flags |
| Analyzer recognizes and holds test results | no |
| Scattergram display uses cell-specific color | no |
| Histogram display uses color with thresholds | no |
| LIS interface formats supported | proprietary (analyzer or vendor specific) |
| • Middleware interface | yes (can use company’s middleware or third-party middleware or connect directly to LIS) |
| • Information transferred to LIS via middleware or LIS interface | numeric results, flagged results |
| Analyzer transmits LOINC codes for results to LIS or middleware | no |
| Lab automation system or workcells to which analyzer has a direct interface | none |
| Barcode symbologies read on specimen tube | Codabar, Code 39, Code 128, Interleaved 2 of 5, Code 93, EAN8, EAN13, EAN128, IATA, Matrix 2 of 5, more |
| • Analyzer allows barcode placement per CLSI standard Auto02-A2 | no |
| No. of onboard reagents required for standard specimen analysis | 2 |
| • Reagents ready to use/Reagent tracking method | yes/barcode reader |
| Onboard diagnostics for troubleshooting | no |
| • Manufacturer can perform diagnostics via remote access | no |
| Warranty provided/Cost of annual service contract (24 h/7 d) | one-year warranty/variable |
| Notes | †also marketed by distributors |